Beta-thalassemia epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
Line 9: Line 9:
*The prevalence of beta-thalassemia carrier is 1.5% of the world population.<ref name="pmid28293406">{{cite journal| author=De Sanctis V, Kattamis C, Canatan D, Soliman AT, Elsedfy H, Karimi M et al.| title=β-Thalassemia Distribution in the Old World: an Ancient Disease Seen from a Historical Standpoint. | journal=Mediterr J Hematol Infect Dis | year= 2017 | volume= 9 | issue= 1 | pages= e2017018 | pmid=28293406 | doi=10.4084/MJHID.2017.018 | pmc=5333734 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28293406  }} </ref>
*The prevalence of beta-thalassemia carrier is 1.5% of the world population.<ref name="pmid28293406">{{cite journal| author=De Sanctis V, Kattamis C, Canatan D, Soliman AT, Elsedfy H, Karimi M et al.| title=β-Thalassemia Distribution in the Old World: an Ancient Disease Seen from a Historical Standpoint. | journal=Mediterr J Hematol Infect Dis | year= 2017 | volume= 9 | issue= 1 | pages= e2017018 | pmid=28293406 | doi=10.4084/MJHID.2017.018 | pmc=5333734 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28293406  }} </ref>
*More than 90% of the cases live in a geographic "belt" extending from the Mediterranean basin and parts of Africa, throughout the Middle East, the Indian subcontinent, Southeast Asia, and Melanesia in to the Pacific Islands.<ref name="pmid23331260">{{cite journal |vauthors=Ladis V, Karagiorga-Lagana M, Tsatra I, Chouliaras G |title=Thirty-year experience in preventing haemoglobinopathies in Greece: achievements and potentials for optimisation |journal=Eur J Haematol |volume=90 |issue=4 |pages=313–22 |date=April 2013 |pmid=23331260 |doi=10.1111/ejh.12076 |url=}}</ref><ref name="pmid25058394">{{cite journal |vauthors=Kountouris P, Lederer CW, Fanis P, Feleki X, Old J, Kleanthous M |title=IthaGenes: an interactive database for haemoglobin variations and epidemiology |journal=PLoS One |volume=9 |issue=7 |pages=e103020 |date=2014 |pmid=25058394 |pmc=4109966 |doi=10.1371/journal.pone.0103020 |url=}}</ref>
*More than 90% of the cases live in a geographic "belt" extending from the Mediterranean basin and parts of Africa, throughout the Middle East, the Indian subcontinent, Southeast Asia, and Melanesia in to the Pacific Islands.<ref name="pmid23331260">{{cite journal |vauthors=Ladis V, Karagiorga-Lagana M, Tsatra I, Chouliaras G |title=Thirty-year experience in preventing haemoglobinopathies in Greece: achievements and potentials for optimisation |journal=Eur J Haematol |volume=90 |issue=4 |pages=313–22 |date=April 2013 |pmid=23331260 |doi=10.1111/ejh.12076 |url=}}</ref><ref name="pmid25058394">{{cite journal |vauthors=Kountouris P, Lederer CW, Fanis P, Feleki X, Old J, Kleanthous M |title=IthaGenes: an interactive database for haemoglobin variations and epidemiology |journal=PLoS One |volume=9 |issue=7 |pages=e103020 |date=2014 |pmid=25058394 |pmc=4109966 |doi=10.1371/journal.pone.0103020 |url=}}</ref>
*There are increases in the number of cases through North America and Europe, which reflects the increased rates of migrations, refugees and adaptation of children.<ref name="pmid31233463">{{cite journal |vauthors=Barry RM, Chretien C, Kirby M, Gallant G, Leppington S, Robitaille N, Corriveau-Bourque C, Stoffman J, Wu J, Leaker M, Klaassen RJ |title=Syrian Refugees and Their Impact on Health Service Delivery in the Pediatric Hematology/Oncology Clinics Across Canada |journal=J Pediatr Hematol Oncol |volume=42 |issue=2 |pages=e107–e109 |date=March 2020 |pmid=31233463 |doi=10.1097/MPH.0000000000001524 |url=}}</ref>


===Incident===
===Incident===

Revision as of 23:17, 31 July 2023

Beta-thalassemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Beta-thalassemia from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Beta-thalassemia epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Beta-thalassemia epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Beta-thalassemia epidemiology and demographics

CDC on Beta-thalassemia epidemiology and demographics

Beta-thalassemia epidemiology and demographics in the news

Blogs on Beta-thalassemia epidemiology and demographics

Directions to Hospitals Treating Beta-thalassemia

Risk calculators and risk factors for Beta-thalassemia epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Maryam Hadipour, M.D.[2]

Overview

Epidemiology and Demographics

Prevalence

There are insufficient data about the exact prevalence of beta-thalassemia.

  • The prevalence of beta-thalassemia carrier is 1.5% of the world population.[1]
  • More than 90% of the cases live in a geographic "belt" extending from the Mediterranean basin and parts of Africa, throughout the Middle East, the Indian subcontinent, Southeast Asia, and Melanesia in to the Pacific Islands.[2][3]
  • There are increases in the number of cases through North America and Europe, which reflects the increased rates of migrations, refugees and adaptation of children.[4]

Incident

  • The incidence of beta-thalassemia is 42,000 per year.[5]
  • Recent studies suggest that around 23000 infants with beta-thalassemia major are born every year and up to 90% of these infants are in low or middle-income countries.[1]

References

  1. 1.0 1.1 De Sanctis V, Kattamis C, Canatan D, Soliman AT, Elsedfy H, Karimi M; et al. (2017). "β-Thalassemia Distribution in the Old World: an Ancient Disease Seen from a Historical Standpoint". Mediterr J Hematol Infect Dis. 9 (1): e2017018. doi:10.4084/MJHID.2017.018. PMC 5333734. PMID 28293406.
  2. Ladis V, Karagiorga-Lagana M, Tsatra I, Chouliaras G (April 2013). "Thirty-year experience in preventing haemoglobinopathies in Greece: achievements and potentials for optimisation". Eur J Haematol. 90 (4): 313–22. doi:10.1111/ejh.12076. PMID 23331260.
  3. Kountouris P, Lederer CW, Fanis P, Feleki X, Old J, Kleanthous M (2014). "IthaGenes: an interactive database for haemoglobin variations and epidemiology". PLoS One. 9 (7): e103020. doi:10.1371/journal.pone.0103020. PMC 4109966. PMID 25058394.
  4. Barry RM, Chretien C, Kirby M, Gallant G, Leppington S, Robitaille N, Corriveau-Bourque C, Stoffman J, Wu J, Leaker M, Klaassen RJ (March 2020). "Syrian Refugees and Their Impact on Health Service Delivery in the Pediatric Hematology/Oncology Clinics Across Canada". J Pediatr Hematol Oncol. 42 (2): e107–e109. doi:10.1097/MPH.0000000000001524. PMID 31233463.
  5. Liaska A, Petrou P, Georgakopoulos CD, Diamanti R, Papaconstantinou D, Kanakis MG; et al. (2016). "β-Thalassemia and ocular implications: a systematic review". BMC Ophthalmol. 16: 102. doi:10.1186/s12886-016-0285-2. PMC 4938965. PMID 27390837.


Template:WikiDoc Sources